文献速递消化系统肿瘤

mFOLFOX联合西妥昔单抗诱导后单药西妥昔单抗维持治疗转移性结直肠癌的II期随机研究

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
PubMed 文献 · Eur J Cancer · 2018-07-24

这项多中心II期随机研究评估了KRAS野生型转移性结直肠癌患者接受mFOLFOX+西妥昔单抗诱导后,分别采用单药西妥昔单抗(A组)或mFOLFOX+西妥昔单抗(B组)维持治疗的疗效与安全性。主要终点9个月无进展生存率显示A组非劣于B组(60% vs 72%,非劣效性p<0.1),两组中位PFS和OS无显著差异,A组≥III级皮疹和感觉神经病变及严重不良事件发生率更低。

要点

  • 单药西妥昔单抗维持治疗9个月PFS率非劣于联合维持(60% vs 72%,非劣效性p<0.1)。
  • 两组中位PFS(9 vs 10个月)和OS(23 vs 27个月)无统计学显著差异。
  • 单药维持组≥III级皮疹、感觉神经病变及严重不良事件发生率更低。

核心结论

  • mFOLFOX+西妥昔单抗诱导后单药西妥昔单抗维持治疗可能是一个有价值的选择,但需III期试验确认。

研究设计与样本

  • 诱导方案为西妥昔单抗+mFOLFOX-6共8个周期(每2周),主要终点为9个月无进展生存率。

主要发现

  • 9个月PFS率A组60%(95%CI 52-69%),B组72%(95%CI 61-83%),非劣效性p<0.1。
  • 中位PFS A组9个月(95%CI 7-10),B组10个月(95%CI 7-13),HR=1.19(95%CI 0.80-1.79)。
  • 中位OS A组23个月(95%CI 19-28),B组27个月(95%CI 18-36),HR=1.24(95%CI 0.85-1.79)。
  • 客观缓解率A组48%(95%CI 39-57%),B组39%(95%CI 27-52%)。
  • ≥III级不良事件发生率A组70%,B组68%;常见≥III级不良事件包括中性粒细胞减少(28% vs 26%)、皮疹痤疮样(15% vs 24%)和感觉神经病变(2% vs 15%);严重不良事件发生率A组20%,B组27%。

临床怎么用

  • 对于KRAS野生型转移性结直肠癌患者,mFOLFOX+西妥昔单抗诱导后可采用单药西妥昔单抗维持治疗,以降低皮疹和神经毒性及严重不良事件风险。

局限性

  • 本研究为II期探索性试验,样本量有限,结论需III期随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This multicentre, randomised, and phase II study evaluated mFOLFOX+cetuximab followed by maintenance mFOLFOX+cetuximab or single-agent cetuximab in metastatic colorectal cancer (mCRC) patients (NCT01161316). PATIENTS AND METHODS: Previously, untreated mCRC patients (wild-type KRAS) were randomised to receive cetuximab+mFOLFOX-6 (8 cycles for 2 weeks) followed by maintenance therapy: single-agent cetuximab (Arm-A) or mFOLFOX-6 + cetuximab (Arm-B) until progression. Primary endpoint was progression-free survival (PFS) at 9 months. RESULTS: One hundred ninety-three patients (median [range] age 60 [33-74] years) were randomised (2:1): 129 Arm-A versus 64 Arm-B. PFS at 9 months (95% confidence interval) showed non-inferiority between arms (Arm-A/Arm-B: 60 [52, 69]%/72 [61, 83]%, p [non-inferiority]<0.1). There were no statistically significant differences in the PFS (Arm-A/Arm-B: 9 [95% CI 7, 10] months/10 [7,13] months, hazard ratio [HR] = 1.19 [0.80, 1.79]) or overall survival (23 [19, 28] months/27 [18, 36] months, HR = 1.24 [0.85, 1.79]) between arms. The objective response rate was also similar (48 [39, 57]%/39 [27, 52]%). The safety profile was similar between arms, and all patients experienced at least one adverse event (AE) (Arm-A/Arm-B grade ≥III AEs: 70%/68%). The most common grade ≥III AEs were as follows: neutropenia (Arm-A/Arm-B: 28%/26%), rash acneiform (15%/24%) and sensory neuropathy (2%/15%) in any group. Arm-A was associated with less grade ≥III rash and sensory neuropathy and a lower rate of serious AEs (20%/27%). CONCLUSION(S): This phase II exploratory trial with a non-inferiority design suggests that maintenance therapy with single-agent cetuximab following mFOLFOX+cetuximab induction could be a valuable option compared with mFOLFOX+cetuximab treatment continuation. We await phase III trials to confirm single-agent cetuximab as maintenance therapy in mCRC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Aranda E, García-Alfonso P, Benavides M, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer. 2018. PMID: 30054049. doi:10.1016/j.ejca.2018.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。